BT1718 in Patients with Advanced Solid Tumours.

Summary

This clinical trial is looking at a drug called BT1718 in adult patients with advanced solid tumours. The main aim of the study is to find the maximum dose of BT1718 that can be given safely to patients; learn more about the potential side effects of BT1718 and how they can be treated and also what happens to BT1718 inside the body.

Timeline

Start

2018-01-24

Primary completion

2023-11-20

Completion

2023-11-20

Outcome

Met primary endpoint

release “The key objectives were met in a Phase I dose escalation sponsored by Cancer Research UK and evaluating safety and tolerability of BT1718.” bicycletherapeutics.com ↗

Drugs

Indications